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ABSTRACT
Background: Insulin resistance is a precursor of numerous chronic
diseases, including cardiovascular disease (CVD). The fasting in-
sulin concentration is considered a reasonable surrogate of insulin
resistance, especially among nondiabetic individuals.
Objective: We aimed to quantitatively summarize the literature on
the association of fasting insulin concentrations with risk of hyper-
tension, stroke, and coronary heart disease (CHD) by conducting
a meta-analysis of prospective cohort studies.
Design: Eligible studies were identified by searching PubMed and
EMBASE through January 2013. Additional information was re-
trieved through Google Scholar or a hand review of the reference
lists from relevant articles. Prospective cohort studies that reported
RRs and corresponding 95% CIs for the association of interest were
identified. Data were extracted independently by 2 investigators,
and the weighted RRs and 95% CIs for the associations were ob-
tained by using a random-effects model.
Results: Of the 22 identified studies, 10 reported results on hyper-
tension (36,617 individuals and 4491 cases), 7 on stroke (27,887
individuals and 1550 cases), and 9 on CHD (22,379 individuals and
1986 cases). Comparison of the highest with the lowest quantile of
fasting insulin concentrations showed a pooled RR (95% CI) of 1.63
(1.35, 1.97) for hypertension, 1.18 (0.87, 1.60) for stroke, and 1.50
(1.28, 1.77) for CHD. Each 50-pmol/L increment in fasting insulin
was associated with a 25% increase in risk of hypertension [RR:
1.25 (1.14, 1.36)] and a 16% increase in risk of CHD [RR: 1.16
(1.10, 1.22)] but was not associated with risk of stroke [RR: 0.999
(0.99, 1.01)].
Conclusions: A higher fasting insulin concentration or hyperinsu-
linemia was significantly associated with an increased risk of hy-
pertension and CHD but not stroke. This meta-analysis suggests that
early fasting insulin ascertainment in the general population may
help clinicians identify those who are potentially at high risk of
CVD. Am J Clin Nutr 2013;98:1543–54.
INTRODUCTION
Insulin resistance is either a precursor or a pivotal component
of numerous chronic diseases (1–5) including cardiovascular
disease (CVD)4 (4), which is the leading cause of morbidity and
mortality and is responsible for .70% of total mortality among
patients with type 2 diabetes (6). Hyperinsulinemia, as a surro-
gate or a compensatory reaction of insulin resistance, may play
an important role in the pathogenesis of CVD. It has been
hypothesized that hyperinsulinemia precedes type 2 diabetes,
which is a major risk factor for developing macrovascular
complications and then becomes associated with an adverse
CVD risk profile, including hypertension (6). However, whether
hyperinsulinemia per se is an independent risk factor for CVD
remains controversial.
Although cross-sectional and longitudinal studies have ex-
plored whether an elevated insulin concentration or insulin
resistance is associated with increased CVD risk (7–12), the
literature is inconsistent regarding perspective relations of fast-
ing insulin concentrations with subsequent risk of hypertension,
stroke, and coronary heart disease (CHD). Many prospective
cohort studies have thus far shown that fasting insulin concen-
trations may predict risk of hypertension (13–20), stroke (21),
and CHD (21–23) independent of other known CVD risk factors,
whereas others have not [hypertension (24, 25), stroke (22, 26–
30), and CHD (28, 29, 31–34)]. Therefore, in this study, we
aimed to quantitatively summarize the literature on the associ-
ations between fasting insulin concentrations and risk of hy-




The meta-analysis was performed based on Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines
(35). First, we conducted a systematic search of published studies
in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) through
January 2013 using the terms “insulin or hyperinsulinemia” and
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“hypertension or blood pressure or stroke or cerebrovascular
accident or myocardial infarction or coronary heart disease” and
“epidemiological studies” and “cohort/ prospective/follow-up/
longitudinal studies” and “survival analysis or proportional haz-
ard model or Cox or hazards ratio or risk.” Next, we reviewed
EMBASE (http://www.elsevier.com/online-tools/embase), Goo-
gle Scholar (http://scholar.google.com/), and the reference lists of
the retrieved articles to identify any studies that were not iden-
tified from the preliminary literature searches. Third, to get addi-
tional data or de novo results for this meta-analysis, we contacted
the authors of primary studies (19, 32).
Selection criteria
Studies were included in the meta-analysis if they met the
following criteria: published in the English language, had a
prospective cohort design, involved a general population, ex-
posure was fasting insulin or hyperinsulinemia, and had an RR
with 95% CI or these data could be derived from reported results.
Data extraction
Two investigators (PX and KH) assessed the eligibility of the
literature independently, and any disagreements were resolved by
consensus. From each retrieved article, we extracted the following
data: specific outcome, name of the first author, year of publication,
study name, country where the study was conducted, proportion
of male sex, age at baseline, follow-up time, total number of in-
dividuals/person-years of follow-up, number of cases, exposure
classification, outcome assessment, covariates that were adjusted in
the analysis, and theRRs estimates with corresponding 95%CIs for
corresponding categories and/or for continuous exposure.
RRs and 95% CIs transformed to their natural logarithms (ln)
were used to compute the corresponding SEs. In studies in which
RRs and 95% CIs were reported as per unit or per SD (either in
pmol/L or mU/mL) increment in fasting insulin concentration,
they were converted to a per 50-pmol/L increment consistently.
If a study did not provide the linear association of fasting insulin
with the outcome of interest, we estimated it by using Greenland
and Longnecker’s method if there were $3 categories for in-
sulin concentrations (36), or we just calculated it under a linear
assumption if there were only 2 categories. If the highest group
of fasting insulin concentrations was an open range (eg, .73.27
pmol/L), then its upper limit was estimated by assuming its
range as wide as the previous one.
In addition, in one study where only stratified RRs (95% CIs)
for incident hypertension by status of family history of hyper-
tension were reported (25), we pooled them with a random-
effects model to get an overall estimate. Moreover, in another
study in which the main effects of hyperinsulinemia (yes or no)
and alcohol intake (yes or no) and their interaction on incidence
of hypertension were reported, we recalculated the stratified
results by alcohol status and pooled them with a random-effects
model to get an overall estimate (24). Furthermore, in 2 other
studies (19, 32), we contacted the authors and obtained de novo
results for the meta-analysis.
Statistical analysis
We pooled RR estimates separately for each outcome using
a random-effects model. We evaluated the statistical heteroge-
neity of the RRs by calculating the I2 statistic; low, moderate, and
high degrees of heterogeneity corresponded to I2 values of 25%,
50%, and 75%, respectively. Publication bias was generally
assessed by using Egger’s (when the numbers of studies pooled
was $3) or Begg’s (when the numbers of studies pooled was
,3) asymmetry test. If publication bias did exist, the Duval and
Tweedie nonparametric “trim and fill” method was used to get
the overall estimate (37). The meta-regression model was used
to detect any potential modifiers.
The average of follow-up years was calculated as the sum of
person-years divided by the total numbers of individuals. If
unavailable, person-years were estimated by multiplying the
number of individuals and the average (mean or median) of
follow-up time. In stratified analyses, we examined subtypes of
stroke (ischemic and hemorrhagic) and duration of follow-up ($
compared with , the median). We also stratified the data by
study region, if possible. Sensitivity analyses evaluated the ef-
fect of removing a single study from the analysis, and, if using
a fixed-effects model, will substantially affect the results. All
analyses were performed by using STATA statistical software
(version 11.0; STATA Corporation LP).
RESULTS
Literature search
As shown in Figure 1, we retrieved 349 related articles from
PubMed. Of these, 334 articles were excluded for one of the
following reasons: 1) a review/meta-analysis, editorial, abstract,
or letter to editor; 2) not published in English; 3) not conducted
in a general population; 4) not relating fasting insulin to an
outcome of interest; 5) fasting insulin was neither a categorical
variable nor a continuous variable in original scale; 6) not
a prospective cohort design; or 7) no RRs with 95% CIs were
reported or such information could not be calculated. In addi-
tion, we identified 7 articles from EMBASE or by hand searching
Google Scholar and the reference list. Therefore, 22 identified
eligible studies were included in this meta-analysis.
Study characteristics
The information extracted from the 22 included independent
studies, all of which were prospective cohort studies and had
participants without prior diagnosed CVD at baseline, is shown in
Table 1. For hypertension (10 studies), the total number of in-
dividuals were 36,617 with 5491 incident cases during an av-
erage 5.7 y of follow-up. For stroke (7 studies), the total number
of individuals was 27,887 with 1550 incidence cases during an
average of 12.3 y of follow-up. For CHD (9 studies), the total
number of individuals was 22,379, with 1986 incidence cases
during an average of 13.8 y of follow-up. The potential con-
founders included in the multivariable-adjusted model are listed
in Table 1.
Fasting insulin concentrations and risk of hypertension
The result from the random-effects meta-analysis of the re-
lation between fasting insulin concentrations and incidence of
hypertension are shown in Figure 2. Eight studies reported RRs
(95% CIs) for the highest compared with the lowest quantile.
As compared with those in the lowest quantile, the pooled RR
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for individuals in the highest quantile was 1.63 (95% CI: 1.35,
1.97) for hypertension. There was moderate heterogeneity
among studies (I2 = 59.6%, P = 0.02). No statistically sig-
nificant evidence of publication bias was observed (Egger’s
test, P = 0.64).
The linear trend analysis involved 9 studies. The combined
RR was 1.25 (1.14, 1.36) for an increment of 50 pmol/L
insulin concentrations. Modest heterogeneity of effect esti-
mates was observed (I2 = 46.6%, P = 0.06), and Egg’s test
for publication bias showed no significant difference (P =
0.22). Neither study region (Eastern compared with Western
countries) nor duration of follow-up modified the observed
associations. Because only 2 studies reported results sepa-
rately by sex, we could not assess the potential effect mod-
ification by sex.
Fasting insulin concentrations and risk of stroke
The pooled RR for the comparison of extreme quantiles of
insulin concentrations was 1.18 (95% CI: 0.87, 1.60) for total
stroke combining data from 6 studies. We saw high heterogeneity
among studies (I2 = 66.1%, P = 0.02), and no evidence of
publication bias (Egger’s test, P = 0.44) (Figure 3).
We found no linear trend, and the pooled RR from 6 studies
was 0.999 (95% CI: 0.99, 1.01) for an increment of 50 pmol/L in
insulin concentrations. There was high heterogeneity among the
FIGURE 1. Study selection process. EMBASE, http://www.elsevier.com/online-tools/embase; Google Scholar, http://scholar.google.com/; PubMed, http://
www.ncbi.nlm.nih.gov/pubmed.
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studies (I2 = 55.8%, P = 0.045). Because there was evidence of
publication bias (Egger’s test, P = 0.01), we used the Duval and
Tweedie’s nonparametric “trim and fill” method to account for
the publication bias. An overall estimate of RR was 0.998 (95%
CI: 0.99, 1.01).
In the stratified analysis, the pooled risk of those in the highest
quantile was 1.24 (0.88, 1.76), with high heterogeneity among 3
studies (I2 = 62.9%, P = 0.07) for ischemic stroke. We observed
no evidence of publication bias (Egger’s P = 0.75). Only one
study reported results on hemorrhagic stroke.
On the basis of 3 studies that reported results in men, we
identified a positive (RR: 1.67; 95%CI: 1.07, 2.60; high compared
with low quantiles) and linear (RR: 1.20; 95% CI: 1.03, 1.40; per
50-pmol/L increment) association between fasting insulin and risk
of stroke. Only one study reported results on women separately.
The duration of follow-up did not substantially modify the ob-
served associations. Because all the studies were conducted in
Western countries, we could not assess the heterogeneity between
eastern and Western countries. Similar results were found in the
studies conducted in US and non-US countries.
Fasting insulin concentrations and risk of CHD
Ten studies were involved in the synthesis of the relation of
fasting insulin concentrations with CHD (Figure 4). On the basis
of available data from 4 studies, the pooled RR from a com-
parison of extreme quantiles of insulin concentrations for CHD
was 1.50 (95% CI: 1.28, 1.77) with no significant heterogeneity
among studies (I2 = 0.0%, P = 0.71). No evidence of publication
bias was observed (Egger’s test, P = 0.28).
According to available data from 8 studies, the pooled risk of
CHD per 50-pmol/L increment in insulin concentration was 1.16
(95% CI: 1.10, 1.22), with modest heterogeneity among studies
(I2 = 11.7%, P = 0.34) and no significant evidence of publication
bias (Egger’s test, P = 0.88).
Only one study reported results in women. On the basis of
6 studies that reported results in men, we identified a positive
dose-response association (RR: 1.13; 95% CI: 1.02, 1.25; per
50-pmol/L increment). Similar results were found in the studies
conducted in the United States and outside of the United States,
and in studies with long-term ($ the average time) and short-
term (, the average time) follow-up periods.
Sensitivity analysis
The findings were consistent when a fixed-effects model was
used (see Supplemental Table 1 under “Supplemental data” in
the online issue). Omission of one study at a time and re-
calculation of the pooled RRs for the rest of the studies showed
that none of the single studies substantially influenced the
pooled RR for hypertension (see Supplemental Table 2 under
“Supplemental data” in the online issue). For stroke, the pooled
association changed from 1.18 (95% CI: 0.87, 1.60) to 1.29
(95% CI: 0.87, 1.91) and 1.31 (95% CI: 0.96, 1.80), respectively,
when Thacker et al’s study (27) and Wieberdink et al’s study
(26) were excluded. For CHD, the pooled estimate was attenu-
ated from 1.50 (95% CI: 1.28, 1.77) to 1.32 (95% CI: 0.99, 1.77)
with the omission of Rasmussen-Torvik et al’s study (21).
Omission of the other studies did not materially change the
results.
FIGURE 2. Multivariable-adjusted RRs and 95% CIs (horizontal lines) for incident hypertension. The pooled estimates (diamond data markers) were
obtained by using a random-effects model. The dots indicate the adjusted RRs by comparing high with low quantiles or per 50-pmol/L increase in fasting
insulin concentrations. The size of the shaded square is proportional to the percentage weight of each study. *De novo data for the meta-analysis.
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DISCUSSION
In this quantitative meta-analysis of prospective cohort studies,
we found significant, positive, and linear associations of fasting
insulin concentrations with risk of hypertension and CHD, but not
stroke. The observed associations were not materially modified
by follow-up period. Our ability to access the potential modifi-
cations by sex or study region was limited by a lack of in-
formation from the primary studies.
FIGURE 3. Multivariable-adjusted RRs and 95% CIs (horizontal lines) for incident stroke and its subtypes. The pooled estimates (diamond data markers)
were obtained by using a random-effects model. The dots indicate the adjusted RRs by comparing high with low quantiles or per 50-pmol/L increase in fasting
insulin concentrations. The size of the shaded square is proportional to the percentage weight of each study.
FIGURE 4. Multivariable adjusted RRs and 95% CIs (horizontal lines) for incident coronary heart disease. The pooled estimates (diamond data markers)
were obtained by using a random-effects model. The dots indicate the adjusted RRs by comparing high with low quantiles or per 50-pmol/L increase in fasting
insulin concentrations. The size of the shaded square is proportional to the percentage weight of each study. *De novo data for the meta-analysis. CHD,
coronary heart disease.
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Strengths and limitations
To date, this was the largest synthesis of prospective cohort
studies to have assessed the associations of fasting insulin
concentrations with incidence of hypertension, stroke, and CHD
in one meta-analysis, which significantly increased the statistical
power to detect potential associations. Also, our conclusions were
strengthened by pooling data for estimating both dose-response
relations and the RRs in a comparison of high with low con-
centrations of insulin. In addition, the positive association docu-
mented between fasting insulin concentration and risk of
hypertension further supports the idea that elevated insulin con-
centrations may increase the risk of CHD through high blood
pressure (BP).
Several limitations of this meta-analysis should be acknowl-
edged. First, the inherent limitations of the primary studies may
have affected our findings. For example, the possibility of re-
sidual confounding or bias due to systematic measurement errors
or unmeasured factors cannot be ruled out. Second, the assay used
to measure fasting insulin in a few studies (21, 28) was unspecific
and had some cross-reactivity with pro-insulin, which may have
confounded our findings. However, the results were not mate-
rially changed after exclusion of these studies in a sensitivity
analysis. Third, the associations of fasting insulin concentrations
with the outcomes of interest found in this meta-analysis were not
completely independent of insulin resistance, because: 1) not all
studies detected insulin resistance status in addition to fasting
insulin concentrations, and 2) the effect of insulin resistance was
impossible to be fully excluded from the models, whereas the
exposure was fasting insulin concentrations. However, some
included studies did adjust blood glucose concentrations in the
model, which may have partially reduced this concern. In ad-
dition, we did not have enough information to assess the po-
tential modifications by sex or study region (Eastern compared
with Western countries).
Comparison with other studies
No published meta-analysis has directly related fasting insulin
to the incidence of hypertension. The current study was the first,
and the findings are consistent with those of a meta-analysis (38)
published in 1992, which reported that fasting insulin concen-
trations were associated with both increased systolic BP and
diastolic BP.
Also, the current study was the first meta-analysis to link
fasting insulin concentrations to risk of stroke. The finding for
stroke was mainly influenced by 2 studies, ie, Thacker et al’s
study (27) and Wieberdink et al’s study (26). When one of them
was excluded, the combined association was somewhat strength-
ened, ie, the pooled RR changed from 1.18 (95% CI: 0.87, 1.60)
to 1.29 (95% CI: 0.87, 1.91) and 1.31 (95% CI: 0.96, 1.80), re-
spectively. One possible explanation is that, only in these 2
studies, SBP, antihypertensive medication use, and$3 lipids were
simultaneously overadjusted in the final model to give a spurious
relation because hypertension and dyslipidemia may be intermediate
variables in addition to strong confounders. In addition, for subtypes
of stroke, the nonsignificant association was likely attributable to
a small number of cases.
Several meta-analyses investigated the associations of fasting
insulin concentrations with the risk of CHD. One meta-analysis
(4) published in 1998 reported a pooled RR of CVD (including
myocardial infarction, death from CHD, and/or electrocardiog-
raphy abnormalities) of 1.18 (95% CI: 1.08, 1.29) with every
50-pmol/L increment in fasting insulin by combining 10 cohort
studies and nested case-control studies. Another meta-analysis
(39) found a positive association between fasting insulin con-
centrations and CVD mortality based on 7 prospective studies
conducted in European countries. In addition, a meta-analysis
published in 2007 included 14 prospective cohort studies and
nested case-control studies (40), which found no significant
association between fasting insulin concentrations and risk of
CHD (mixed incidence and mortality).
Notably, a recent meta-analysis published in 2012 focusing on
insulin resistance and incidence of combined cardiovascular
events found no association between fasting insulin concentra-
tions and risk of CHD (41). The null association found in that
study may be explained by 1) mixed prospective cohort studies
and nested case-control studies, 2) combined multiple health
endpoints, and 3) not having updated the findings from the
Atherosclerosis Risk in Communities Study published in 2010
(21) with 960 CHD cases.
Potential mechanisms
Fasting insulin concentrations and risk of hypertension
Experimental studies suggest that insulin, a well-established
inotropic agent (42), can increase cardiac output (43), blood
volume through stimulating secretion of vasopressin (an anti-
diuretic) (44), and renal sodium retention (45). In addition,
insulin can increase vascular tone by increasing basal concen-
trations of calcium in cytosol of vascular smooth muscle cells,
stimulating the rennin-angiotensin system (46), and stimulating
the secretion of endohelin-1 (47)—a vascular constrictor.
Although the likelihood of high BP causing elevated insulin
concentrations cannot be excluded (48), the possibility should be
small because changes in insulin concentrations usually precede
the presence of obvious hypertension in metabolic diseases (49).
In addition, a large body of evidence lends credence to an in-
crease of BP by insulin (50, 51), but no existing evidence with
respect to the underlying mechanism supports the idea that hy-
pertension might cause hyperinsulinemia.
Fasting insulin concentrations and risk of CHD and stroke
In addition to traditional risk factors (eg, hypertension and
dyslipidemia), insulin can increase risk of CHD and stroke
through nontraditional CVD risk factors, including endothelial
dysfunction, increased inflammation, and increased coagulation
(52). First, insulin resistance is associated with endothelial
dysfunction and the accumulation of reactive oxygen species in
the vessel wall that help to initiate and maintain the athero-
sclerotic process. Second, insulin resistance can affect adipocyte
function, giving rise to the generation of a number of in-
flammatory molecules (eg, C-reactive protein, complement C3),
which play a crucial role in the atherosclerotic process. In ad-
dition, insulin resistance is associated with increased platelet
activation and an increased concentration and activity of pro-
thrombotic factors, which thereby ensures the presence of
a prothrombotic milieu that could increase the risk of athero-
thrombotic events.
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Summary
In conclusion, the meta-analysis of prospective cohort studies
found that an elevated fasting insulin concentration or hyper-
insulinemia was significantly associated with an increased risk of
hypertension and CHD. Our study suggests that early ascer-
tainment of fasting insulin may help clinicians identify those who
are potentially at high risk of CVD.
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